Transcription of BENCHMARKING SUCCESS - pugatch-consilium.com
{{id}} {{{paragraph}}}
Example: bachelor of science
BENCHMARKING SUCCESS - pugatch-consilium.com
BENCHMARKING SUCCESS . Evaluating the Orphan Regulation and its impact on patients and rare disease R&D in the European Union SECTION. This report was initiated and funded by Shire International GmbH. Shire is now part of Takeda. The views represented here are those of the authors only. Copyright Pugatch Consilium 2019. The moral right of the authors has been asserted. All rights reserved. Without limiting the rights under copyright reserved above, no part of this publication may be reproduced, stored or introduced into a retrieval system, or transmitted, in any form or by any means (electronic, mechanical, photocopying, recording or otherwise), without the prior written permission of both the copyright owner and the publisher.
BENCHMARKING SUCCESS 7 EXECUTIVE SUMMARY Developing a novel biopharmaceutical product is an expensive, risky and time-consuming enterprise that takes between 10 to …
Loading..
Information
Domain:
Source:
Link to this page:
Please notify us if you found a problem with this document: